MBRX News and Press, Moleculin Biotech Inc. From 07/28/22

Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases PR Newswire – Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better ...

Moleculin Biotech ( NASDAQ: MBRX ) said preliminary data from the second group of its phase 1a study of WP1122 showed that the COVID-19 drug candidate was safe in healthy people. The second cohort consisted of 8 people who were dosed with 16 mg/kg or placebo i...

Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK PR Newswire – Preliminary results of second cohort in the first-in-human Phase 1a allow Company to proceed to 32 mg/kg dose of WP1122 in th...

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK PR Newswire – Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in...

Moleculin Biotech (NASDAQ:MBRX +4.3%) said on Thursday it had begun dosing its first human in a Phase 1a study evaluating the safety and pharmacokinetics of its lead candidate, WP1122, to treat COVID-19. "Based on the antiviral effect of WP1122 demonstrated in preclinical models, we remain co...

Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 PR Newswire – Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish ...

Moleculin to Present at the H.C. Wainwright Global Investment Conference PR Newswire HOUSTON , May 19, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips DecisionPoint Systems (NYSEMKT: DPSI ) stock is leading our top gainers. Target (NYSE: TGT ) stock is at the top of our losers list. Earnings reports are behind much of this morning’s stock movement....

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TNXP leads our gainers but only because of a reverse stock split IMPP is our top loser as it retreats from a meme stock rally yesterday. Many stocks are on the move alongside Q1 2022 earnings reports today. Source...

Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings BBLN +16%. Blue Water Vaccines (BWV) +14%.  ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech...